Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00440492 · ClinicalTrials.gov registry record · Phase 1

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

A Phase 1 study of Arthritis, Rheumatoid, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
9
Study locations

NCT00440492: Completed Phase 1 study of Arthritis, Rheumatoid, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00440492 is a Phase 1 study of Arthritis, Rheumatoid that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00440492, a Phase 1 study of Arthritis, Rheumatoid, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
9
Study locations

Study Summary

The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

Conditions Studied

Interventions

  • DRUG PLA-695

Study Locations (9)

California

  • - Los Angeles
  • - Palo Alto

New York

  • - Lake Success
  • - Rochester

North Carolina

  • - Charlotte

Ohio

  • - Columbus

British Columbia

  • - Vancouver

Ontario

  • - Mississauga

Quebec

  • - Montreal

Trial Details

FieldValue
Start Date 2006-12
Est. Completion 2007-11
Phase Phase 1

What the finished NCT00440492 record still lists

NCT00440492 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which PLA-695 is the first listed.

NCT00440492 lists 9 locations in 7 states (California, New York, North Carolina).

Frequently Asked Questions

What is clinical trial NCT00440492 about?

NCT00440492 is a clinical study titled "Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis". The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

What is the current status of trial NCT00440492?

This trial is currently completed. It is a Phase 1 study. The study started on 2006-12. Estimated completion is 2007-11.

What conditions does trial NCT00440492 study?

This clinical trial studies the following conditions: Arthritis, Rheumatoid.

What interventions are being tested in trial NCT00440492?

The interventions under investigation include: PLA-695 (DRUG).

Who is sponsoring clinical trial NCT00440492?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00440492 being conducted?

This trial has 9 study locations across California, New York, North Carolina, Ohio, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00440492, the US trial registry maintained by the National Library of Medicine. NCT00440492 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.